MedTrace Logo

Molecular Characterization of Gliomas Using a Broad Next Generation Sequencing (NGS)Panel

NCT05486247 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2022-08-03

No results posted yet for this study

Summary

Gliomas are the most common malignant primary brain tumors with poor prognosis. The genotyping of tumors using NGS platforms enables the identification of genetic alterations that constitute diagnostic, prognostic and predictive biomarkers.Here in, we investigated the molecular profile of 32 tumor samples from 32 patients with high grade gliomas by implementing a broad 80-gene targeted NGS panel while reporting their clinicopathological characteristics and outcomes.

Conditions

  • Malignant Glioma

Sponsors & Collaborators

  • Hellenic Cooperative Oncology Group

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-04
Primary Completion
2021-12-01
Completion
2022-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05486247 on ClinicalTrials.gov